Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets

Defining the mutational landscape of classic Hodgkin lymphoma is still a major research goal. New targeted next-generation sequencing (NGS) techniques may identify pathogenic mechanisms and new therapeutic opportunities related to this disease. We describe the mutational profile of a series of 57 cHL cases, enriched in Hodgkin and Reed-Sternberg (HRS) cells. Overall, the results confirm the presence of strong genomic heterogeneity. However, several variants were consistently detected in genes related to relevant signaling pathways, such as GM-CSF/IL-3, CBP/EP300, JAK/STAT, NF-kappaB, and numerous variants of genes affecting the B-cell receptor (BCR) pathway, such as BTK, CARD11, BCL10, among others. This unexpectedly high prevalence of mutations affecting the BCR pathway suggests some requirement for active BCR signaling for cHL cell viability. Additionally, incubation of a panel of cHL cellular models with selective BTK inhibitors in vitro constrains cell proliferation and causes cell death. Our results indicate new pathogenic mechanisms and therapeutic opportunities in this disease.

[1]  R. Küppers,et al.  Hodgkin lymphoma. , 2012, The Journal of clinical investigation.

[2]  Andrew J. Bannister,et al.  Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy. , 2015, Cancer research.

[3]  P. Hari,et al.  Ibrutinib in Refractory Classic Hodgkin's Lymphoma. , 2015, The New England journal of medicine.

[4]  Yuan Qi,et al.  Reproducibility of Variant Calls in Replicate Next Generation Sequencing Experiments , 2015, PloS one.

[5]  O. Elemento,et al.  Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. , 2015, Blood.

[6]  Iván Fernández-Vega,et al.  Bruton’s tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma , 2015, Virchows Archiv.

[7]  R. Gascoyne,et al.  The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing , 2014, Leukemia.

[8]  J. Byrd,et al.  Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. , 2014, The New England journal of medicine.

[9]  A. Salar,et al.  Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation , 2014, Leukemia.

[10]  Trevor J Pugh,et al.  A systematic approach to assessing the clinical significance of genetic variants , 2013, Clinical genetics.

[11]  Steven J. M. Jones,et al.  Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. , 2013, Blood.

[12]  J. Miller,et al.  Predicting the Functional Effect of Amino Acid Substitutions and Indels , 2012, PloS one.

[13]  Juan F. García,et al.  Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin’s lymphoma , 2012, Haematologica.

[14]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[15]  W. Wilson,et al.  Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations , 2011, Modern Pathology.

[16]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[17]  Raul Rabadan,et al.  Inactivating mutations of acetyltransferase genes in B-cell lymphoma , 2010, Nature.

[18]  Wentao Yang,et al.  Mutations of NFKBIA in biopsy specimens from Hodgkin lymphoma. , 2010, Cancer genetics and cytogenetics.

[19]  Gwendoline Dubois,et al.  Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. , 2009, Blood.

[20]  Kai Ye,et al.  Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..

[21]  W. Klapper,et al.  TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma , 2009, The Journal of experimental medicine.

[22]  Mauno Vihinen,et al.  Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain , 2009, Immunological reviews.

[23]  R. Foà,et al.  Interleukin (IL)‐3/granulocyte macrophage‐colony stimulating factor/IL‐5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS‐related tyrosine kinase 3 receptor , 2009, British journal of haematology.

[24]  Jan Delabie,et al.  Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma , 2008, Science.

[25]  T. Mattfeldt,et al.  Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation , 2006, Oncogene.

[26]  H. Stein,et al.  Inactivating I kappa B epsilon mutations in Hodgkin/Reed–Sternberg cells , 2003, The Journal of pathology.

[27]  V. Diehl,et al.  Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. , 2003, Blood.

[28]  A. van den Berg,et al.  Low frequency of FAS mutations in Reed-Sternberg cells of Hodgkin's lymphoma. , 2002, The American journal of pathology.

[29]  D. Niedzwiecki,et al.  Long-term follow-up of Hodgkin's disease trial. , 2002, The New England journal of medicine.

[30]  G. Lenz,et al.  Defective octamer-dependent transcription is responsible for silenced immunoglobulin transcription in Reed-Sternberg cells. , 2001, Blood.

[31]  R. Siebert,et al.  Array-based DNA methylation analysis in classical Hodgkin lymphoma reveals new insights into the mechanisms underlying silencing of B cell-specific genes , 2012, Leukemia.